Released Mar 12, 2015, after the close
10-K filed Mar 12, 2015, 71 days after period end · 0001171843-15-001376
Q4 2014 · 10-K
Revenue$30.36M$30.36M +9.0% vs Q4 2013+19.3% vs Q3 2014
Net Income-$19.00K-$19.00K N/M vs Q4 2013N/M vs Q3 2014
EPS Diluted$0.00$0.00 N/M vs Q4 2013−100.0% vs Q3 2014
Gross Profit$13,863,000+15.1%
Operating Income$2,121,000N/M
Operating Cash Flowderived$1,263,000+1.1%
Margins · derived
Gross margin45.7%+2.4 pt vs Q4 2013
Operating margin7.0%+10.4 pt vs Q4 2013
Net margin-0.1%+2.7 pt vs Q4 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 |
|---|---|---|---|---|
| Revenue | $30.36M | $27.85M | $28.25M | $29.03M |
| Net Income | -$19.00K | -$756.00K | $1.20M | $738.00K |
| EPS Diluted | $0.00 | -$0.02 | $0.04 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR